Cumberland Pharmaceuticals (NASDAQ:CPIX) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) from a buy rating to a hold rating in a report released on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Cumberland Pharmaceuticals Price Performance

CPIX opened at $5.47 on Friday. The stock has a fifty day simple moving average of $3.53 and a two-hundred day simple moving average of $3.49. The company has a current ratio of 0.95, a quick ratio of 0.84 and a debt-to-equity ratio of 0.25. The company has a market cap of $81.94 million, a price-to-earnings ratio of -11.16 and a beta of -0.06. Cumberland Pharmaceuticals has a 12-month low of $1.85 and a 12-month high of $6.26.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.13). The business had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million. Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC purchased a new stake in shares of Cumberland Pharmaceuticals in the fourth quarter worth $1,358,000. Dimensional Fund Advisors LP grew its stake in shares of Cumberland Pharmaceuticals by 11.1% in the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after acquiring an additional 27,980 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in shares of Cumberland Pharmaceuticals by 2.3% in the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock worth $631,000 after acquiring an additional 4,200 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Cumberland Pharmaceuticals by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after acquiring an additional 5,653 shares during the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Cumberland Pharmaceuticals in the fourth quarter worth $192,000. 15.51% of the stock is owned by hedge funds and other institutional investors.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.